Papers

Randomised controlled trial of enalapril and ß blockers in non- diabetic chronic renal failure

Department of Nephrology, Hopital Necker, Paris, France Laboratoires de Biostatistique, Hopital Necker, Paris, France Department of Nephrology, Hopital Sud, Amiens, France Hopital de Bois-Guillaume, Rouen, France Hopital de Rangueil, Toulouse, France, Hopital Maison-Blanche, Reims, France Hopital Teron, Paris, France Correspondence to: Professor T Hannedouche, Department of Nephrology, Hopitaux Universitaires de Strasbourg, 67091, Strasbourg, France.

Abstract

Objective : To compare the ability of angiotensin converting enzyme inhibitors and ß blockers to slow the development of end stage renal failure in non-diabetic patients with chronic renal failure.
Design : Open randomised multicentre trial with three year follow up.
Setting : Outpatient departments of six French hospitals.
Patients : 100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 µmol/l). 52 randomised to enalapril and 48 to ß blockers (conventional treatment).
Interventions : Enalapril or ß blocker was combined with frusemide and, if necessary, a calcium blocker or centrally acting drug in patients whose diastolic pressure remained above 90 mm Hg.
Results : 17 patients receiving conventional treatment and 10 receiving enalapril developed end stage renal failure. The cumulative renal survival rate was significantly better in the enalapril group than in the conventional group (P<0.05). The slope of the reciprocal serum creatinine concentration was steeper in the conventionally treated patients (- 6.89x10^-5l/µmol/month) than in the enalapril group (-4.17x10^-5l/µmol/month; P<0.05). No difference in blood pressure was found between groups.
Conclusion : In hypertensive patients with chronic renal failure enalapril slows progression towards end stage renal failure compared with ß blockers. This effect was probably not mediated through controlling blood pressure.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., Fink, J. C. (2009). The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease. Arch Intern Med 169: 1156-1162 [Abstract] [Full text]  
• O'Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., Larson, E. B. (2009). Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?. ANN INTERN MED 150: 717-724 [Abstract] [Full text]  
• Lely, A. T., van der Kleij, F. G.H., Kistemaker, T. J., Apperloo, A. J., de Jong, P. E., de Zeeuw, D., Navis, G. (2008). Impact of the Preintervention Rate of Renal Function Decline on Outcome of Renoprotective Intervention. CJASN 3: 54-60 [Abstract] [Full text]  
• Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., Levey, A. S., for the AIRPD Study Group, (2007). Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. J. Am. Soc. Nephrol. 18: 1959-1965 [Abstract] [Full text]  
• Mizobuchi, M., Morrissey, J., Finch, J. L., Martin, D. R., Liapis, H., Akizawa, T., Slatopolsky, E. (2007). Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Vitamin D Analog Suppresses the Progression of Renal Insufficiency in Uremic Rats. J. Am. Soc. Nephrol. 18: 1796-1806 [Abstract] [Full text]  
• Chiurchiu, C., Remuzzi, G., Ruggenenti, P. (2005). Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses. J. Am. Soc. Nephrol. 16: S58-S63 [Abstract] [Full text]  
• Jafar, T. H., Schmid, C. H., Stark, P. C., Toto, R., Remuzzi, G., Ruggenenti, P., Marcantoni, C., Becker, G., Shahinfar, S., de Jong, P. E., de Zeeuw, D., Kamper, A.-L., Strangaard, S., Levey, A. S. (2003). The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 18: 2047-2053 [Abstract] [Full text]  
• Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R., Levey, A. S., for the AIPRD Study Group*, (2003). Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. ANN INTERN MED 139: 244-252 [Abstract] [Full text]  
• Appel, G. B., Radhakrishnan, J., Avram, M. M., DeFronzo, R. A., Escobar-Jimenez, F., Campos, M.M., Burgess, E., Hille, D. A., Dickson, T. Z., Shahinfar, S., Brenner, B. M. (2003). Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study. Diabetes Care 26: 1402-1407 [Abstract] [Full text]  
• Remuzzi, G., Ruggenenti, P., Perico, N. (2002). Chronic Renal Diseases: Renoprotective Benefits of Renin-Angiotensin System Inhibition. ANN INTERN MED 136: 604-615 [Abstract] [Full text]  
• Bakris, G. L. (2001). A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients. Arch Intern Med 161: 2661-2667 [Abstract] [Full text]  
• Elung-Jensen, T., Heisterberg, J., Kamper, A.-L., Sonne, J., Strandgaard, S., Larsen, N. E. (2001). High serum enalaprilat in chronic renal failure. Journal of Renin-Angiotensin-Aldosterone System 2: 240-245 [Abstract]  
• Ruggenenti, P., Perna, A., Remuzzi, G. (2001). ACE Inhibitors to Prevent End-Stage Renal Disease: When to Start and Why Possibly Never to Stop: A Post Hoc Analysis of the REIN Trial Results. J. Am. Soc. Nephrol. 12: 2832-2837 [Abstract] [Full text]  
• Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., Becker, G., Himmelmann, A., Bannister, K., Landais, P., Shahinfar, S., de Jong, P. E., de Zeeuw, D., Lau, J., Levey, A. S., the ACE Inhibition in Progressive Renal Disease St, (2001). Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data. ANN INTERN MED 135: 73-87 [Abstract] [Full text]  
• Toto, R. (2001). Angiotensin II Subtype 1 Receptor Blockers and Renal Function. Arch Intern Med 161: 1492-1499 [Abstract] [Full text]  
• Schmid, C. H. (2001). Using Bayesian Inference to Perform Meta-Analysis. Eval Health Prof 24: 165-189 [Abstract]  
• Cinotti, G. A., Zucchelli, P. C. (2001). Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant 16: 961-966 [Abstract] [Full text]  
• Bakris, G. L., Weir, M. R. (2000). Angiotensin-Converting Enzyme Inhibitor-Associated Elevations in Serum Creatinine: Is This a Cause for Concern?. Arch Intern Med 160: 685-693 [Abstract] [Full text]  
• Feldman, R. D., Campbell, N., Larochelle, P., Bolli, P., Burgess, E. D., Carruthers, S. G., Floras, J. S., Haynes, R. B., Honos, G., Leenen, F. H.H., Leiter, L. A., Logan, A. G., Myers, M. G., Spence, J. D., Zarnke, K. B. (1999). 1999 Canadian recommendations for the management of hypertension. CMAJ 161: S1-17 [Abstract] [Full text]  
• Kissmeyer, L., Kong, C., Cohen, J., Unwin, R. J., Woolfson, R. G., Neild, G. H. (1999). Community nephrology: audit of screening for renal insufficiency in a high risk population. Nephrol Dial Transplant 14: 2150-2155 [Abstract] [Full text]  
• Hausberg, M., Barenbrock, M., Hohage, H., Muller, S., Heidenreich, S., Rahn, K.-H. (1999). ACE Inhibitor Versus ß-Blocker for the Treatment of Hypertension in Renal Allograft Recipients. Hypertension 33: 862-868 [Abstract] [Full text]  
• Moore, M. A., Epstein, M., Agodoa, L., Dworkin, L. D. (1999). Current Strategies for Management of Hypertensive Renal Disease. Arch Intern Med 159: 23-28 [Abstract] [Full text]  
• Toto, R., Shultz, P., Raij, L., Mitchell, H., Shaw, W., Ramjit, D., Toh, J., Shahinfar, S. (1998). Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment. Hypertension 31: 684-691 [Abstract] [Full text]  
• Reardon, L. C., Macpherson, D. S. (1998). Hyperkalemia in Outpatients Using Angiotensin-Converting Enzyme Inhibitors: How Much Should We Worry?. Arch Intern Med 158: 26-32 [Abstract] [Full text]  
• Kario, K., Kanai, N., Nishiuma, S., Fujii, T., Saito, K., Matsuo, T., Matsuo, M., Shimada, K. (1997). Hypertensive Nephropathy and the Gene for Angiotensin-Converting Enzyme. Arterioscler. Thromb. Vasc. Bio. 17: 252-256 [Abstract] [Full text]  
• National High Blood Pressure Education Program Wor, (1996). 1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension. Arch Intern Med 156: 1938-1947 [Abstract]  
• Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F.E., Motolese, M., Ponticelli, C., Ritz, E., Zucchelli, P., The Angiotensin-Converting-Enzyme Inhibition in Pr, (1996). Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. NEJM 334: 939-945 [Abstract] [Full text]  
• Hazar, D. B., Tso, L. (1995). Enalapril and (beta) blockers in chronic renal failure. BMJ 310: 129-129 [Full text]  
• (1995). Who needs nine ACE inhibitors?. DTB 33: 1-3 [Abstract] [Full text]  
• (1994). ACE INHIBITORS FOR NONDIABETIC RENAL FAILURE. JWatch General 1994: 1-1 [Full text]